Morphea
Information
- Disease name
- Morphea
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03351114 | Completed | Phase 2 | Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea | September 1, 2018 | March 10, 2020 |
| NCT01799174 | Completed | N/A | Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea | May 2012 | September 13, 2019 |
| NCT04752397 | Completed | The Influence of Extracorporeal Photopheresis on Skin Sclerosis | February 12, 2021 | September 6, 2021 | |
| NCT02222038 | Completed | N/A | Genetic Variants in Linear Localized Scleroderma | August 2014 | October 31, 2017 |
| NCT03630198 | Completed | Phase 4 | Pain Outcomes Following Intralesional Corticosteroid Injections | October 1, 2018 | September 1, 2019 |
| NCT04922736 | Enrolling by invitation | N/A | Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases | June 7, 2021 | September 2024 |
| NCT01808937 | Recruiting | Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository | May 2007 | January 2028 | |
| NCT02411643 | Terminated | Early Phase 1 | Molecular Effects of Topical Calcipotriene on Morphea | March 2015 | April 2016 |
| NCT03740724 | Terminated | Phase 1/Phase 2 | A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) | December 18, 2019 | April 21, 2022 |
| NCT04656704 | Withdrawn | Early Phase 1 | Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease | January 1, 2020 | January 1, 2022 |
| NCT00230373 | Withdrawn | Phase 3 | Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study | November 2005 | June 2007 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012344